Home » Topics » BioWorld Science

BioWorld Science
RSS

University of Illinois discloses FOXM1 inhibitors

Nov. 4, 2019

Oligomannate approved in China for mild to moderate AD

Nov. 4, 2019

Neuropore Therapies divulges PIK3C3 inhibitors

Nov. 4, 2019

Promentis Pharmaceuticals announces update on phase II development of SXC-2023

Nov. 4, 2019

OB-002 significantly reduces both primary and metastatic breast cancer in vivo

Nov. 4, 2019

BCX-9250 enters phase I development for treatment of fibrodysplasia ossificans progressiva

Nov. 4, 2019

BGS-2019: a new GMPS inhibitor for the treatment of lupus nephritis

Nov. 4, 2019

Rinvoq meets primary and all ranked secondary endpoints in phase III SELECT-PsA 2 study

Nov. 4, 2019

ORYX announces positive early clinical data for oncolytic virus ParvOryx

Nov. 4, 2019

NexImmune receives IND clearance for phase I/II study of NEXI-001

Nov. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...